Generics - Pricing

Filter

Current filters:

Pricing

Popular Filters

19 to 43 of 1772 results

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Sweden’s Meda rejects Mylan’s takeover overture

Sweden’s Meda rejects Mylan’s takeover overture

06-04-2014

After a day of rumor and speculation about a takeover approach from US generic firm Mylan, Swedish drugmaker…

GenericsMedaMergers & AcquisitionsMylan Laboratories

Brazil’s CMED approves price adjustment of medicines to 3.35%

04-04-2014

Brazil's National Health Surveillance Agency ANVISA’s office of pharmaceutical drug market regulation…

BrazilPharmaceuticalPricingSouth America

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

Actavis opens new Asia Pacific regional headquarters in Singapore

03-04-2014

Ireland-headquartered generics major Actavis has officially opened its new regional office in Singapore…

ActavisAsia-PacificGenericsManagementMarkets & Marketing

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

Pamplona buys majority stake in US generic firm Alvogen

02-04-2014

Pamplona Capital Management has as acquired a majority stake in privately-held US company Alvogen, which…

AlvogenGenericsMergers & Acquisitions

Hikma’s US facility back in compliance

Hikma’s US facility back in compliance

02-04-2014

Hikma Pharmaceuticals, Jordan's largest pharmaceutical company, has received a close-out letter from…

GenericsHikma PharmaceuticalsJordanPharmaceuticalRegulation

European generic drug makers sets out priorities for EU Trade Policy

European generic drug makers sets out priorities for EU Trade Policy

02-04-2014

European Generic Medicines Association (EGA) revealed this morning that its president, Nick Haggar, has…

EuropeGenericsPoliticsRegulationRest of the World

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Actavis forks out $100 million for Thai generics firm

Actavis forks out $100 million for Thai generics firm

02-04-2014

Ireland-headquartered US generic major Actavis has acquired Silom Medical Company, a privately held generic…

Asia-PacificAurobindo PharmaGenericsMergers & AcquisitionsSilom Medical CompanyTeva Pharmaceutical Industries

Prasco to market the authorized generic of Lilly’s Evista in USA

01-04-2014

Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

Price cuts mean PBS can afford new medicines, says Medicines Australia

Price cuts mean PBS can afford new medicines, says Medicines Australia

01-04-2014

As of today in Australia, price cuts come into effect for 121 medicines, and trade group Medicines Australia…

Asia-PacificAustraliaHealthcarePharmaceuticalPricing

Actavis prevails in Lialda patent dispute in USA

Actavis prevails in Lialda patent dispute in USA

31-03-2014

US generics major Actavis says that the US Court of Appeals for the Federal Circuit has reversed a lower…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsShireUSA

Study produces map of pharma industry and API production in Brazil

Study produces map of pharma industry and API production in Brazil

28-03-2014

Brazil is failing to produce the number of active pharmaceutical ingredients in order to produce the…

BrazilGenericsMarkets & MarketingProductionSouth America

Philippine government increasing financial support for health care spending

28-03-2014

The size of the Philippine pharmaceutical market, now worth around $3.2 billion, is expected to expand…

Asia-PacificFinancialGenericsMarkets & MarketingPharmaceutical

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

UK’s NICE does not recommend Janssen’s Stelara for psoriatic arthritis

28-03-2014

Final draft guidance from the UK health care costs watchdog the National Institute for Health and Care…

Anti-Arthritics/RheumaticsJanssenJohnson & JohnsonNorthern EuropePharmaceuticalPricingRegulationStelara InjectionUK

New HIV/AIDS drug will be offered through Brazil’s SUS

New HIV/AIDS drug will be offered through Brazil’s SUS

27-03-2014

A medicine that combines tenofovir (Gilead’s Viread) and lamivudine (GlaxoSmithKline’s Combivir)…

Anti-viralsBlanver FarmoquimicaBrazilGenericsLamivudineProductionSouth AmericaTenofovir Disoproxil Fumarate

Mylan prevails in breach of contract case against GlaxoSmithKline

Mylan prevails in breach of contract case against GlaxoSmithKline

27-03-2014

US generics major Mylan reveals that, after a trial in the US District Court for the District of New…

GenericsGlaxoSmithKlineLegalMylan LaboratoriesNeurologicalparoxetinePaxil-CR

Breakthrough therapies for rare diseases command premium pricing

Breakthrough therapies for rare diseases command premium pricing

26-03-2014

The global orphan drugs market presents plenty of opportunities for new drug development – while there…

PharmaceuticalPricingRare diseasesResearch

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

19 to 43 of 1772 results

Back to top